Takeda Pharmaceutical (TAK) Cash & Equivalents (2017 - 2026)
Takeda Pharmaceutical (TAK) posted quarterly Cash & Equivalents of $2.9 billion for Q2 2026, up 19.56% year-over-year from $2.4 billion in Q2 2025, and down 23.78% quarter-over-quarter from $3.8 billion in Q1 2026.
Takeda Pharmaceutical (TAK) Cash & Equivalents (2017 - 2026) Analysis & Trends
Takeda Pharmaceutical's Cash & Equivalents history runs 10 years deep, the most recent figure standing at $2.9 billion for Q2 2026.
- In Q2 2026, Cash & Equivalents rose 19.56% year-over-year to $2.9 billion; the TTM figure through Jun 2026 stood at $2.9 billion (up 19.56% YoY), while the FY2026 annual figure was $4.0 billion, up 56.36% from the prior year.
- Cash & Equivalents for Q2 2026 stood at $2.9 billion, down from $3.8 billion in the prior quarter.
- The five-year high for Cash & Equivalents was $7.3 billion in Q1 2022, with the low at $2.0 billion in Q4 2023.
- The 5-year median for Cash & Equivalents is $3.9 billion (2026), against an average of $4.0 billion.
- The sharpest annual moves came in 2023 and 2024: Cash & Equivalents tumbled 61.89% in 2023, then jumped 161.49% in 2024.
- Takeda Pharmaceutical's Cash & Equivalents stood at $4.8 billion in 2022, then slumped by 59.77% to $2.0 billion in 2023, then soared by 66.61% to $3.3 billion in 2024, then surged by 30.94% to $4.3 billion in 2025, then sank by 32.04% to $2.9 billion in 2026.
- Business Quant data shows TAK's Cash & Equivalents at $2.9 billion in Q2 2026, $3.8 billion in Q1 2026, and $4.3 billion in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash & Equiv. (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.89 Bn | 42.93 Bn | - | 1.11 Bn |
| 2 | Teva Pharmaceutical Industries | 42.98 Bn | 39.33 Bn | 2.15 Bn | 3.66 Bn |
| 3 | Zoetis | 31.54 Bn | 29.86 Bn | 1.05 Bn | 1.48 Bn |
| 4 | Takeda Pharmaceutical | 28.61 Bn | 22.81 Bn | 5.10 Bn | 2.89 Bn |
| 5 | United Therapeutics | 22.15 Bn | 19.48 Bn | 683.80 Mn | 1.80 Bn |
| 6 | Viatris | 18.75 Bn | 17.86 Bn | 1.46 Bn | 886.50 Mn |
| 7 | Neurocrine Biosciences | 15.56 Bn | 15.17 Bn | 935.80 Mn | 332.40 Mn |
| 8 | Elanco Animal Health | 11.74 Bn | 11.21 Bn | 798.00 Mn | 530.00 Mn |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.95 Bn | - | 164.00 Mn |
| 10 | Alkermes | 8.11 Bn | 7.46 Bn | 397.90 Mn | 511.53 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 2.89 Bn |
| Mar 31, 2026 | 3.79 Bn |
| Dec 31, 2025 | 4.26 Bn |
| Sep 30, 2025 | 4.63 Bn |
| Jun 30, 2025 | 2.42 Bn |
| Mar 31, 2025 | 2.52 Bn |
| Dec 31, 2024 | 3.25 Bn |
| Sep 30, 2024 | 5.76 Bn |
| Jun 30, 2024 | 5.17 Bn |
| Mar 31, 2024 | 3.09 Bn |
| Dec 31, 2023 | 1.95 Bn |
| Sep 30, 2023 | 2.20 Bn |
| Jun 30, 2023 | 2.31 Bn |
| Mar 31, 2023 | 4.03 Bn |
| Dec 31, 2022 | 4.85 Bn |
| Sep 30, 2022 | 5.78 Bn |
| Jun 30, 2022 | 5.00 Bn |
| Mar 31, 2022 | 7.31 Bn |
| Dec 31, 2021 | 6.37 Bn |
| Sep 30, 2021 | 5.52 Bn |